MedPath

ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Phase 4
Completed
Conditions
Hypotrichosis
Interventions
Drug: bimatoprost ophthalmic solution 0.03%
Drug: bimatoprost vehicle solution
First Posted Date
2011-10-07
Last Posted Date
2013-05-22
Lead Sponsor
Allergan
Target Recruit Count
88
Registration Number
NCT01448525

A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Completed
Conditions
Macular Edema
Interventions
Drug: dexamethasone intravitreal implant 0.7 mg
First Posted Date
2011-10-04
Last Posted Date
2013-02-18
Lead Sponsor
Allergan
Target Recruit Count
87
Registration Number
NCT01445626

BOTOX® Prophylaxis in Patients With Chronic Migraine

Completed
Conditions
Migraine Disorders
Interventions
Biological: botulinum toxin Type A
First Posted Date
2011-09-13
Last Posted Date
2019-01-08
Lead Sponsor
Allergan
Target Recruit Count
1168
Registration Number
NCT01432379

Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion

Phase 4
Completed
Conditions
Retinal Vein Occlusion
Macular Edema
Interventions
Drug: dexamethasone intravitreal implant
Biological: ranibizumab
First Posted Date
2011-09-02
Last Posted Date
2019-04-18
Lead Sponsor
Allergan
Target Recruit Count
307
Registration Number
NCT01427751

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

First Posted Date
2011-08-31
Last Posted Date
2015-10-02
Lead Sponsor
Allergan
Target Recruit Count
6
Registration Number
NCT01426113

Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne

Phase 1
Withdrawn
Conditions
Acne Vulgaris
Interventions
Drug: Fixed Combination dapsone/adapalene Formulation A Gel
Drug: dapsone 5% gel
Drug: Fixed Combination dapsone/adapalene Formulation B Gel
Drug: adapalene 0.3% gel
First Posted Date
2011-08-30
Last Posted Date
2012-11-19
Lead Sponsor
Allergan
Registration Number
NCT01425320

Inter-rater and Intra-rater Reliability of the Global Eyebrow Assessment Scale

Completed
Conditions
Healthy Volunteers
Interventions
Drug: No Intervention
First Posted Date
2011-08-09
Last Posted Date
2012-10-29
Lead Sponsor
Allergan
Target Recruit Count
112
Registration Number
NCT01412086

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

Completed
Conditions
Retinal Vein Occlusion
Macular Edema
Interventions
Drug: dexamethasone intravitreal implant 0.7 mg
First Posted Date
2011-08-08
Last Posted Date
2013-04-16
Lead Sponsor
Allergan
Target Recruit Count
289
Registration Number
NCT01411696

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

Phase 2
Completed
Conditions
Age-related Macular Degeneration
Interventions
Drug: AGN-150998
Drug: ranibizumab
Other: Sham Injection
First Posted Date
2011-07-19
Last Posted Date
2019-04-16
Lead Sponsor
Allergan
Target Recruit Count
271
Registration Number
NCT01397409

Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines

Phase 4
Completed
Conditions
Glabellar Frown Lines
Interventions
Drug: normal saline (placebo)
Biological: botulinum toxin Type A
First Posted Date
2011-07-12
Last Posted Date
2012-09-25
Lead Sponsor
Allergan
Target Recruit Count
40
Registration Number
NCT01391312
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy